2,356 results match your criteria ivig compared


Evaluation of the FCGR2B polymorphism in children with immune thrombocytopenia.

Minerva Pediatr (Torino) 2021 Dec 3. Epub 2021 Dec 3.

Department of Public Health and Pediatrics, School of Medicine, University of Turin, Turin, Italy -

Background: Childhood immune thrombocytopenia (ITP) is an immune-mediated disease characterized by an isolated low platelet count. Pathogenesis of ITP is complex but many patients have platelet specific autoantibodies leading to accelerated clearance of opsonized platelets by Fc-gamma receptor (FcγR) bearing phagocytes, particularly in the spleen. In humans, there are three main types of Fcγ receptors: high-affinity FcγRI and low-affinity FcγRII and FcγRIII. Read More

View Article and Full-Text PDF
December 2021

[Predictive value of serum ferritin and a new predictive model for intravenous immunoglobulin resistance in Kawasaki disease].

Zhonghua Er Ke Za Zhi 2021 Dec;59(12):1080-1085

Department of Pediatric Nephrology, Quanzhou Women's and Children's Hospital, Quanzhou 362000, China.

To evaluate the predictive value of serum ferritin (SF) and construct a novel predictive model for intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD) (IVIGRKD). The clinical data of 422 children with KD from January 2017 to December 2019 in Quanzhou Women's and Children's Hospital were retrospectively analyzed. According to the response to IVIG, they were divided into IVIG-resistant group and IVIG-sensitive group. Read More

View Article and Full-Text PDF
December 2021

Intravenous immunoglobulin regulates anti-desmoglein 3 IgG production in B220 antibody-producing cells in mice with pemphigus vulgaris.

J Invest Dermatol 2021 Nov 27. Epub 2021 Nov 27.

Department of Dermatology, Keio University School of Medicine, Tokyo, Japan. Electronic address:

Intravenous immunoglobulin (IVIG) is a treatment option for intractable cases of pemphigus vulgaris (PV), an autoimmune blistering disease caused by autoantibodies against desmoglein 3 (Dsg3). To investigate the efficacy of IVIG on autoantibody secretion, we produced PV model mice by adoptive transfer of immunized Dsg3 splenocytes to Rag2 mice. We found that circulating anti-Dsg3 IgG ELISA titer decreased in PV model mice after 5 days of treatment with IVIG compared with PBS-treated mice, whereas the F(ab') fragment did not suppress the anti-Dsg3 IgG titer. Read More

View Article and Full-Text PDF
November 2021

IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti-B Cell Therapies.

Neurol Neuroimmunol Neuroinflamm 2022 Jan 29;9(1). Epub 2021 Nov 29.

From Thomas Jefferson University, Philadelphia, PA; and the University of Athens Medical School, Greece.

Background And Objectives: Describe the unique functions of immunoglobulin G4 (IgG4) in IgG4-neurologic disorders (IgG4-ND) and explain why, in contrast to their IgG1-counterparts, they respond poorly to intravenous immune globulin (IVIg) but effectively to anti-B cell therapies.

Methods: The IgG4 structure and isotype switch, B cells and plasmablasts relevant to IgG4 production, and IgG4-induced disruption of the targeted antigens are reviewed and compared with IgG1-mediated autoimmune ND, where IVIg inhibits IgG1-triggered inflammatory effects.

Results: The main IgG4-ND include muscle-specific kinase myasthenia; nodal/paranodal chronic inflammatory demyelinating polyradiculoneuropathy with antibodies to neurofascin-155, contactin-1/caspr-1, or pan-neurofascins; antileucine-rich, glioma-inactivated-1 and contactin-associated protein-like 2 associated-limbic encephalitis, Morvan syndrome, or neuromyotonia; and anti-IgLON5 disorder. Read More

View Article and Full-Text PDF
January 2022

Increased Expression of Pyroptosis in Leukocytes of Patients with Kawasaki Disease.

Diagnostics (Basel) 2021 Nov 3;11(11). Epub 2021 Nov 3.

Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.

Background: Kawasaki disease (KD) is a form of febrile vasculitis that primarily occurs in children. It can cause inflammation of the coronary arteries, which leads to aneurysms. The pathogenesis of coronary arteries may be associated with apoptosis or pyroptosis mediated by caspases activity, but this idea has not been discussed much in KD. Read More

View Article and Full-Text PDF
November 2021

LGI1 antibody encephalitis: acute treatment comparisons and outcome.

J Neurol Neurosurg Psychiatry 2021 Nov 25. Epub 2021 Nov 25.

Department of Neurology and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

Objective: To compare acute treatment responses and long-term outcome in leucine-rich glioma-inactivated 1 (LGI1) antibody encephalitis.

Methods: Retrospective case series of 118 patients with LGI1 antibody encephalitis evaluated at Mayo Clinic across all US sites from 1 May 2008 to 31 March 2019. Patient clinical data were identified and analysed through the neuroimmunology laboratory and electronic medical record. Read More

View Article and Full-Text PDF
November 2021

A Machine Learning Model to Predict Intravenous Immunoglobulin-Resistant Kawasaki Disease Patients: A Retrospective Study Based on the Chongqing Population.

Front Pediatr 2021 8;9:756095. Epub 2021 Nov 8.

School of Medical Informatics, Chongqing Medical University, Chongqing, China.

We explored the risk factors for intravenous immunoglobulin (IVIG) resistance in children with Kawasaki disease (KD) and constructed a prediction model based on machine learning algorithms. A retrospective study including 1,398 KD patients hospitalized in 7 affiliated hospitals of Chongqing Medical University from January 2015 to August 2020 was conducted. All patients were divided into IVIG-responsive and IVIG-resistant groups, which were randomly divided into training and validation sets. Read More

View Article and Full-Text PDF
November 2021

IVIG Compared to IVIG Plus Infliximab in Multisystem Inflammatory Syndrome in Children.

Pediatrics 2021 Sep 22. Epub 2021 Sep 22.

Department of Pediatrics, Section of Infectious Diseases, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO.

View Article and Full-Text PDF
September 2021

Circulating Natural Autoantibodies to HER2-Derived Peptides Performed Antitumor Effects on Oral Squamous Cell Carcinoma.

Front Pharmacol 2021 5;12:693989. Epub 2021 Nov 5.

Beijing Institute of Dental Research, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.

Natural autoantibodies play a crucial role in destruction of malignant tumors due to immune surveillance function. Epidermal growth factor receptor 2 (HER2) has been found to be highly expressed in a variety of epithelial tumors including oral squamous cell carcinoma (OSCC). The present study was thus undertaken to investigate the effect of anti-HER2 natural autoantibodies on OSCC. Read More

View Article and Full-Text PDF
November 2021

Efficacy of add-on therapy with intravenous immunoglobulin in steroid hyporesponsive DRESS syndrome.

Clin Transl Sci 2021 Nov 18. Epub 2021 Nov 18.

Division of Allergy, Asthma, and Clinical Immunology, Department of Internal Medicine, Chonnam National University Medical School, Chonnam National University Hospital, Gwangju, Korea.

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare, potentially life-threatening, delayed, drug-induced hypersensitivity reaction. Immediate withdrawal of the culprit drug and administration of systemic corticosteroids is the most widely accepted treatment. However, it is difficult to manage patients with DRESS syndrome who are not responsive to systemic steroids. Read More

View Article and Full-Text PDF
November 2021

Cost-effectiveness of eltrombopag versus intravenous immunoglobulin for the perioperative management of immune thrombocytopenia.

Blood Adv 2021 Nov 15. Epub 2021 Nov 15.

McMaster University, Hamilton, Canada.

Eltrombopag has been shown to be non-inferior to intravenous immunoglobulin (IVIG) for improving perioperative platelet counts in patients with immune thrombocytopenia (ITP) in a randomized trial; thus, cost is an important factor for treatment and policy decisions. We used patient-level data from the trial to conduct a cost-effectiveness analysis comparing perioperative eltrombopag 50mg daily starting dose, with IVIG 1 or 2g/kg (according to local practice) from a Canadian public healthcare payer's perspective over the observation period, from preoperative day 21 to postoperative day 28. Resource utilization data were obtained from the trial data (eltrombopag, n=38; IVIG, n=36) and unit costs were collected from the Ontario Schedule of Benefits, Ontario Drug Formulary, and secondary sources. Read More

View Article and Full-Text PDF
November 2021

A nationwide study on Sydenham's chorea: Clinical features, treatment and prognostic factors.

Eur J Paediatr Neurol 2021 Nov 6;36:1-6. Epub 2021 Nov 6.

Pediatric Rheumatology, Pediatric University Department, Azienda Ospedaliera Universitaria Pisana, University of Pisa, Pisa, Italy.

Objectives: Sydenham's Chorea (SC) is a neuropsychiatric disorder and a major manifestation of acute rheumatic fever. The erroneous assumption that SC is a benign and self-limiting disease, has led to a lack of high-quality scientific evidence of the therapeutical and prognostic features of SC.

Study Design: We retrospectively analyzed the medical records of patients <18-years old with SC in 17 Italian pediatric centers. Read More

View Article and Full-Text PDF
November 2021

Immunomodulator use in paediatric severe sepsis and septic shock.

Ann Acad Med Singap 2021 10;50(10):765-772

Department of Paediatrics, KK Women's and Children's Hospital, Singapore.

Introduction: The use of drugs that modulate the immune system during paediatric severe sepsis and septic shock may alter the course of disease and is poorly studied. This study aims to characterise these children who received immunomodulators and describe their clinical outcomes.

Methods: This is a retrospective chart review of patients with severe sepsis and septic shock admitted into the paediatric intensive care unit (PICU). Read More

View Article and Full-Text PDF
October 2021

Clinical outcomes of intravenous immunoglobulin therapy in COVID-19 related acute respiratory distress syndrome: a retrospective cohort study.

BMC Pulm Med 2021 Nov 8;21(1):354. Epub 2021 Nov 8.

Intensive Care Unit, Hazm Mebaireek General Hospital, Doha, Qatar.

Background: Intravenous immunoglobulin (IVIG) has been used as an immunomodulatory therapy to counteract severe systemic inflammation in coronavirus disease 2019 (COVID-19). But its use in COVID-19 related acute respiratory distress syndrome (ARDS) is not well established.

Methods: We conducted a retrospective analysis of electronic health records of COVID-19 patients admitted to intensive care units (ICUs) at Hazm Mebaireek General Hospital, Qatar, between March 7, 2020 and September 9, 2020. Read More

View Article and Full-Text PDF
November 2021

Acute haemorrhagic leukoencephalitis (AHLE) - our experience and a short review.

J Neuroimmunol 2021 Dec 13;361:577751. Epub 2021 Oct 13.

Department of Neuropathology, National Institute of Mental Health and Neuroscience (NIMHANS), Bangalore, India.

Background: Acute haemorrhagic leukoencephalitis (AHLE), a rare variant of acute disseminated encephalomyelitis (ADEM), often presents differently from classical ADEM, thereby posing a diagnostic challenge to the clinician.

Aim: To report AHLE, its clinic-radiological manifestations, process of diagnosis and prognosis.

Method And Results: Eight patients presented with altered sensorium, acute focal deficits with or without seizures. Read More

View Article and Full-Text PDF
December 2021

Anxiety among the parents of pediatric patients receiving IVIG therapy during the Covid-19 pandemic.

Turk J Pediatr 2021 ;63(5):801-810

Department of Psychology, İstanbul Gelişim University Faculty of Economics, Administrative and Social Sciences, İstanbul, Turkey.

Background: Symptomatic COVID-19 cases in children occur mostly in those with primary immunodeficiency (PID), chronic lung diseases, and heart disease. Guidelines recommend that patients with PID continue to use their regular medication during the pandemic.

Objectives: This study aimed to evaluate anxiety related to COVID-19 in the parents of patients receiving intravenous immunoglobulin (IVIG) treatment in our hospital and to evaluate the effect of their anxiety on the continuity of treatment. Read More

View Article and Full-Text PDF
November 2021

Efficacy of therapies in the treatment of Guillain-Barre syndrome: A network meta-analysis.

Medicine (Baltimore) 2021 Oct;100(41):e27351

Shenzhen Hospital of Beijing University of Chinese Medicine (Longgang), Shenzhen, China.

Background: Guillain-Barre syndrome (GBS) is a disease with the features of acuteness, paralysis, inflammation, and in peripheral nerves. There are many current treatment options with varying efficacy, and to assess their effectiveness, we performed a network meta-analysis (NMA). The study protocol was registered at PROSPERO (CRD: 42019119178). Read More

View Article and Full-Text PDF
October 2021

A Comparison of Clinical, Electro-Diagnostic, Laboratory, and Treatment Outcome Differences in a Cohort of HIV-Infected and HIV-Uninfected Patients With Myasthenia Gravis.

Front Neurol 2021 15;12:738813. Epub 2021 Oct 15.

Department of Neurology, University of KwaZulu-Natal, Durban, South Africa.

There is limited literature comparing the clinical parameters and treatment outcomes in HIV-infected and HIV-uninfected myasthenia gravis (MG) patients. The aim of the study was to investigate the clinical differences and treatment outcomes in the two categories of patients, particularly the safe use of immunosuppressive therapy in immunocompromised patients. The study was a retrospective analysis of medical records of MG patients from the neuromuscular unit at Inkosi Albert Luthuli Central Hospital in Kwa-Zulu Natal between 2003 and 2019. Read More

View Article and Full-Text PDF
October 2021

Epidemiology of Kawasaki disease in Australia using two nationally complete datasets.

J Paediatr Child Health 2021 Oct 30. Epub 2021 Oct 30.

Faculty of Medicine and Health, Discipline of Child and Adolescent Health, The University of Sydney, Sydney, New South Wales, Australia.

Aim: The incidence of Kawasaki disease (KD) is reported to be increasing in some populations. We sought to describe long-term trends in the incidence and epidemiology of KD in Australia over 25 years.

Methods: Two nationally complete administrative datasets relevant to KD in Australia were analysed and compared. Read More

View Article and Full-Text PDF
October 2021

Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.

Lancet Child Adolesc Health 2021 Dec 27;5(12):852-861. Epub 2021 Oct 27.

Biostatistics Research Center, Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, USA; Maria Fareri Children's Hospital at Westchester Medical Center, New York Medical College, Valhalla, NY, USA.

Background: Although intravenous immunoglobulin (IVIG) is effective therapy for Kawasaki disease, 10-20% of patients have recrudescent fever as a sign of persistent inflammation and require additional treatment. We aimed to compare infliximab with a second infusion of IVIG for treatment of resistant Kawasaki disease.

Methods: In this multicentre comparative effectiveness trial, patients (aged 4 weeks to 17 years) with IVIG resistant Kawasaki disease and fever at least 36 h after completion of their first IVIG infusion were recruited from 30 hospitals across the USA. Read More

View Article and Full-Text PDF
December 2021

Multisystem Inflammatory Syndrome Following SARS-CoV-2 Infection in Children: One Year after the Onset of the Pandemic in a High-Incidence Area.

Viruses 2021 10 7;13(10). Epub 2021 Oct 7.

Department of Pediatrics, Istituto di Ricovero e Cura a Carattere Scientifico St. Orsola Polyclinic, University of Bologna, 40138 Bologna, Italy.

SARS-CoV-2 infection in children can trigger cardiovascular manifestations potentially requiring an intensive treatment and defining a new entity named Multisystem Inflammatory Syndrome in Children (MIS-C), whose features partially overlap with Kawasaki Disease (KD). A cross-sectional study including all diagnoses of MIS-C and KD from April 2020 to May 2021 in our metropolitan area was conducted evaluating clinical, laboratory (including immunological response, cytokines, and markers of myocardial damage), and cardiac (coronary and non-coronary) features at onset of the diseases. Evolution of ventricular dysfunction, valve regurgitations, and coronary lesions was documented. Read More

View Article and Full-Text PDF
October 2021

A Case of Evans Syndrome and Unstable Angina.

J Med Cases 2021 Oct 29;12(10):415-418. Epub 2021 Sep 29.

Abington Memorial Hospital, Philadelphia, PA 19001, USA.

Evans syndrome (ES) is characterized by autoimmune hemolytic anemia (AIHA) and immune-mediated thrombocytopenia. It is more common in the pediatric population than in adults. ES has been reported to be associated with thrombotic events and rarely can lead to acute coronary syndrome (ACS). Read More

View Article and Full-Text PDF
October 2021

Profile of Urinary Cytokines in Kawasaki Disease: Non-Invasive Markers.

Diagnostics (Basel) 2021 Oct 8;11(10). Epub 2021 Oct 8.

Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.

This cohort study aimed to investigate urinary cytokines expression to help identify a less invasive method of cytokine detection for Kawasaki disease (KD). Patients with confirmed KD were recruited. Patients with fever or urinary tract infection (UTI) were enrolled as control groups. Read More

View Article and Full-Text PDF
October 2021

Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis.

Clinicoecon Outcomes Res 2021 11;13:883-892. Epub 2021 Oct 11.

Mallinckrodt Pharmaceuticals, Hampton, NJ, USA.

Background: Relapses are common among patients with multiple sclerosis (MS) despite treatment with disease-modifying therapies. Repository corticotropin injection (RCI, Acthar Gel), plasmapheresis (PMP), and intravenous immunoglobulin (IVIg) are alternative therapies for MS relapse. There is a dearth of economic assessments of these therapies for the acute exacerbations of MS. Read More

View Article and Full-Text PDF
October 2021

Clinical Features in Children With Kawasaki Disease Shock Syndrome: A Systematic Review and Meta-Analysis.

Front Cardiovasc Med 2021 21;8:736352. Epub 2021 Sep 21.

Jilin Children's Medical Center, Children's Hospital of Changchun, Changchun, China.

This study aimed to identify the clinical features of Kawasaki disease shock syndrome (KDSS) in children. The case-control studies of KDSS and KD children up until April 30, 2021 were searched in multiple databases. The qualified research were retrieved by manually reviewing the references. Read More

View Article and Full-Text PDF
September 2021

Role of Intravenous Immunoglobulin in Necrotizing Autoimmune Myopathy.

J Clin Rheumatol 2021 Sep 23. Epub 2021 Sep 23.

From the Division of Rheumatology and Clinical Immunology, Department of Medicine Departments of Neurology and Pathology (Neuropathology), University of Pittsburgh School of Medicine, Pittsburgh, PA.

Background/objective: Immune-mediated necrotizing myopathy (IMNM) is a subtype of myositis that is associated with a refractory phenotype and poorer prognosis. The aim of the study was to provide single large center experience of outcomes of intravenous immunoglobulin (IVIg) for patients with IMNM using longitudinally collected data.

Methods: This case series longitudinally evaluated 4 of the 6 myositis core set measures at baseline and at 3 and 6 months after IVIg on 20 adult IMNM patients from 2014 to 2019 at the University of Pittsburgh. Read More

View Article and Full-Text PDF
September 2021

Multicomponent Vaccines against Group A Streptococcus Can Effectively Target Broad Disease Presentations.

Vaccines (Basel) 2021 Sep 15;9(9). Epub 2021 Sep 15.

The National Institute of Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, London EN6 3QG, UK.

Group A Streptococcus (GAS) is an important global human pathogen, with a wide range of disease presentations, from mild mucosal infections like pharyngitis to invasive diseases such as toxic shock syndrome. The effect on health and mortality from GAS infections is substantial worldwide, particularly from autoimmune sequelae-like rheumatic heart disease (RHD), and there is currently no licenced vaccine. We investigated protein antigens targeting a broad range of GAS disease presentations as vaccine components in individual and combination formulations. Read More

View Article and Full-Text PDF
September 2021

Effect of Intravenous IgM-Enriched Immunoglobulins on Presepsin and Other Sepsis Biomarkers.

Front Pharmacol 2021 8;12:717349. Epub 2021 Sep 8.

Dipartimento di Medicina e Chirurgia, Università Degli Studi di Salerno, Baronissi, Italy.

Patients in septic shock with low IgG and IgM serum concentrations have higher mortality rates compared to those with normal immunoglobulin levels and, therefore, there is a rational explanation to administer intravenous IgM-enriched immunoglobulins to septic patients in ICU. Aim of this study is to evaluate the effectiveness of intravenous IgM-enriched immunoglobulins in decreasing several sepsis biomarker concentrations. 26 sepsis patients were enrolled in this observational cohort study and Nitric Oxide, Endocan, Pentraxin and presepsin serum levels were measured during their first 3 days of ICU stay. Read More

View Article and Full-Text PDF
September 2021

Predictive value of Albumin-Bilirubin grade for intravenous immunoglobulin resistance in a large cohort of patients with Kawasaki disease: a prospective study.

Pediatr Rheumatol Online J 2021 Sep 25;19(1):147. Epub 2021 Sep 25.

Department of Pediatric Cardiology, West China Second University Hospital, Sichuan University, 610041, Chengdu, Sichuan, China.

Background: Intravenous immunoglobulin (IVIG) resistance prediction is one of the primary clinical issues and study hotspots in KD. This study aimed to prospectively investigate the value of albumin-bilirubin grade (ALBI) in predicting IVIG resistance in KD and to assess whether ALBI has more predictive value or accuracy than either ALB or TBil alone in predicting IVIG resistance.

Methods: A total of 823 patients with KD were prospectively enrolled. Read More

View Article and Full-Text PDF
September 2021

Intravenous immunoglobulin and the current risk of moderate and severe anaphylactic events, a cohort study.

Clin Exp Immunol 2021 Dec 17;206(3):384-394. Epub 2021 Oct 17.

Northern Clinical School, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.

This large cohort study from the US Premier Healthcare Database evaluated the risk and predictors of anaphylaxis in association with intravenous immunoglobulin (IvIg) therapy in the inpatient and outpatient setting. Data were collected retrospectively (January 2009-December 2018) from 24 919 patients administered IgPro10 IvIg, median age 54 years. Immunoglobulins of interest were IgPro10 and other IvIg given before or after IgPro10. Read More

View Article and Full-Text PDF
December 2021